These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30337472)

  • 1. Cost recovery by Health Canada and drug safety: a time-series analysis.
    Lexchin J
    CMAJ Open; 2018; 6(4):E471-E477. PubMed ID: 30337472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
    Lexchin J; Ahmed T
    CMAJ Open; 2015; 3(3):E286-91. PubMed ID: 26442227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
    Lexchin J
    Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
    Lexchin J
    BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study.
    Lexchin J
    PLoS One; 2020; 15(11):e0240966. PubMed ID: 33137156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.
    Lexchin J
    Healthc Policy; 2016 Nov; 12(2):65-75. PubMed ID: 28032825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
    Lexchin J
    Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
    Eadie A; MacGregor A; Wallach J; Ross J; Herder M
    BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
    Samuel AM; Rathi VK; Grauer JN; Ross JS
    Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.